Pilot Study: Paclitaxel plus Bevacizumab followed by FEC100 in HER2-negative locally (stage IIIB/IIIC) advanced breast cancer.
Phase 2
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000009978
- Lead Sponsor
- PO Kanagawa Breast Oncology Group(KBOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patient with a history of the past of the breast cancer 2) Ineligible based on decision of an investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate
- Secondary Outcome Measures
Name Time Method non residual tumor classification rate pathological complete response rate safety progression-free survival 3years survival rate
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie paclitaxel and bevacizumab synergy in HER2-negative locally advanced breast cancer?
How does paclitaxel-bevacizumab neoadjuvant therapy compare to standard FEC100-based regimens in stage IIIB/IIIC breast cancer?
Which biomarkers predict response to anti-VEGF (bevacizumab) plus taxane (paclitaxel) in locally advanced HER2-negative breast cancer?
What are the key adverse events associated with sequential paclitaxel-bevacizumab and FEC100 in phase II breast cancer trials?
How do anti-angiogenic agents like bevacizumab influence outcomes in HER2-negative locally advanced breast cancer compared to other VEGF inhibitors?